SLCO1A2, the official full name is solute carrier organic anion transporter family member 1A2. It is also known as solute carrier family 21 member 3. It is encoded by the SLCO1A2 gene in humans and belongs to the SLC21A family of solute carriers. This gene is conserved in chimpanzee, monkey, cow, rat, dog, mouse and chicken. It has been reported that 113 organisms have orthologs with this gene. SLCO1A2 is widely expressed in brain, lung and 2 other tissues, and is involved in cellular uptake of organic ions in the liver.
|Basic Information of SLCO1A2|
|Protein Name||Solute carrier organic anion transporter family member 1A2|
|Aliases||OATP, OATP1, OATP1A2, SLC21A3|
|Organism||Homo sapiens (Human)|
SLCO1A2 is also known as solute carrier family 21 member 3 which belongs to SLC21A family of solute carriers. SLCO1A2 is shown to be a sodium-independent transporter and can mediate cellular uptake of organic ions in the liver. The substrates of this transporter include bromosulphophthalein, bile acids, and some steroidal compounds. Multiple transcript variants can be generated because of different splicing of SLCO1A2 gene. SLCO1A2 can be selectively inhibited by the grapefruit juice component naringin. SLCO1A2 is involved in the cellular uptake of methotrexate and plays a critical role in the elimination of MTX. In addition, a microRNA binding site polymorphism in SLCO1A2 is associated with delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia. In addition, SLCO1A2 was identified as novel loci in progressive supranuclear palsy, and this will provide mechanistic insights for therapeutic strategies. SLCO1A2 polymorphisms are associated with chloroquine/primaquine responses. SLCO1A2 regulates cellular uptake of ochratoxin A, and this can aggravate OTA toxicity.
Fig.1 Representation of transport and exchange of methotrexate in the brain. (Mikkelsen, 2011)
This article indicates that SLCO1A2 is identified as novel loci in progressive supranuclear palsy, and this will provide mechanistic insights for therapeutic strategies.
This article identifies the NF-kB inhibition binding site on the promoter region of SLCO1A2.
This article indicates that microRNA binding site polymorphism in SLCO1A2 is associated with the risk of delayed methotrexate elimination for acute lymphoblastic leukemia, and concludes that polymorphism (rs4149009 G > A) might affect MTX pharmacokinetics through interfering with the function of miRNAs.
This article shows that SLCO1A2 polymorphisms are associated with chloroquine/primaquine responses.
This article shows that SLCO1A2 regulates cellular uptake of Ochratoxin A, and this can aggravate OTA toxicity.
With years of extensive experience in the field of membrane protein preparation, we have established advanced Magic™ membrane protein production platform, to facilitate the projects of our worldwide customers. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLCO1A2 antibody development services.
Creative Biolabs is dedicated to offering the most superior products to our customers to best maximize the success of your projects. With professional scientists and skillful technologies, we are glad to provide membrane protein services but not limited to those. For more detailed information, please feel free to contact us.